Novartis has a well-earned reputation for introducing innovative and effective medicines for disease areas in need of new therapies- particularly in oncology, transplantation and ophthalmology.  We are also known for producing new and ever- more efficient medicines for the more common cardiovascular and respiratory diseases, as well as for diseases affecting the brain.
 

Novartis currently has a total of 75 development projects in the pipeline, of which 70% are in trial phases II or III, or in registration.  90% of these projects offer new modes of action or are treatments meeting unmet clinical needs.
 

In 2006, Novartis commitment to research and product innovation was recognised worldwide, with the Scrip Award for best product pipeline within the pharmaceutical industry.
 

• Oncology 
  Management and treatment of various cancers, Iron Overload and Acromegaly (excess growth hormone in adults)
• Infectious diseases, Transplantation and Immunology
  Organ transplants
• Ophthalmology
  Age-related macular degeneration, Dry eye

• Cardiovascular and Metabolism
  Hypertension, Diabetes, Atherosclerosis
• Neuroscience
  Alzheimer’s, Parkinson’s, Epilepsy, Depression, Schizophrenia, Anxiety, Chronic Pain, Multiple sclerosis
• Respiratory
  Asthma, COPD, Allergies, Bronchitis, Cystic Fibrosis
• Dermatology
  Onychomycosis (fungal nail infection), Psoriasis, Atopic dermatitis, Acne
• Arthritis/Bone/Gastrointestinal/Urology
  Rheumatoid arthritis, Osteoarthritis, Urinary incontinence